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ABSTRACT
The increasing scope and availability of genetic testing options for patients 
suffering from cancer has raised questions about how to use results of molecular 
diagnostics to inform patient care. For some biomarkers (e.g. BRAF mutations in 
melanoma), standards exist that outline treatments for individuals harboring 
aberrations in the biomarker; however for the vast majority of genomic abnormalities, 
few guidelines exist. Clinical decision making and the therapeutic approach for a 
patient with a given cancer characterized by aberrations in different genes may 
be aided by the use of a biomarker actionability framework that provides levels of 
evidence regarding whether and how a molecular abnormality can be considered a 
therapeutically relevant biomarker. A gene may be considered theoretically actionable 
if it has a basis of actionability, such that clinically available drugs can target a gene 
product that drives the cancer or is differentially expressed in tumor versus normal 
elements. Herein, we discuss a possible framework for developing guidelines for 
actionability, as they relate to genomically-based cancer therapeutics.
INTRODUCTION
Over the last decade, there has been a breathtaking 
fall in the cost of genomics, accompanied by a precipitous 
rise in the efficiency of the technology that enables rapid 
sequencing of human genomes. As a result, biomarkers, 
especially those representing genomic alterations, are 
becoming increasingly vital to the classification and 
treatment of cancer. Biomarkers are herein defined as 
measurable molecular or cellular elements linked to a 
health outcome or state; they can be functionally important 
in tumors (“oncogenic drivers”) or may be differentially 
expressed in the malignant versus normal tissue without 
functional impact (“passengers”). 
A biomarker is actionable if it is oncogenic and/or 
differentially expressed on tumor cells, and a treatment 
approach can be crafted that mitigates its oncogenic 
potential and/or permits the recognition and destruction 
of tumor cells. Driver aberrations can be targeted by 
interfering with their function, or by exploiting them to 
identify and select tumor cells for destruction. Passenger 
biomarkers, however, can also be targeted, if they are 
used to select cancer cells for destruction by virtue of the 
targeting agent recognizing differences between cancer 
and normal elements.
Diagnostic laboratories around the world are now 
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offering tests that sequence either full exomes or gene 
panels in cancer samples. It is expected that, in the near 
future, more clinical-grade transcriptomic and proteomic 
tests will also become available. While genomics have 
traditionally been performed for research purposes, in 
the United States, tests performed under the auspices 
of the Clinical Laboratory Improvement Amendments 
(CLIA) can be utilized to inform patient care; currently, 
a variety of genomic tests, from single gene appraisal to 
multi-panel tests on anywhere from about 10 to over 400 
genes [1], full exomic sequencing [2], and transcriptomics 
[3] are obtainable from CLIA-certified laboratories. 
The hope is that patients can be matched to approved 
targeted therapies or clinical trials with investigational 
targeted therapies on the basis of the molecular profiles 
of their cancer. However, our understanding of the way 
in which biomarkers defined by genomics are predictive 
of therapeutic response lags behind the widespread 
availability of next generation sequencing (NGS) and 
other diagnostic tests and the pace of development of 
targeted therapies. 
From the clinical management viewpoint, 
biomarkers may broadly be divided into three groups. 
In the first category are a handful of biomarkers that are 
clinically validated, may be in widely accepted treatment 
guidelines (such as the NCCN [4] or FDA guidelines 
[5]) and may have approved drugs that target them. 
These include BRAF V600 mutation for melanoma [6], 
EGFR mutation [7] and ALK fusion for lung cancer [8], 
HER2 amplification or overexpression for breast cancer 
[9], and KRAS mutation for colorectal cancer [10]. In 
the second category are biomarkers that have a basis 
for “actionability” having one or more of the following 
factors: (i) clinical evidence suggesting responsiveness 
to one or more drugs or classes when the biomarkers are 
present; (ii) the biomarkers are direct targets of approved/
investigational drugs; (iii) the biomarkers are part of a 
pathway that can be targeted by approved/investigational 
drugs; or (iv) the biomarkers bear similarity to other 
biomarkers that are deemed actionable. Finally, the 
third category includes biomarkers for which there is no 
discernable link to actionability. 
The framework also includes a rationale for 
actionability in which strength of evidence for a biomarker 
is mapped to *highest* strength of evidence for a 
given cancer. In this paper, we propose an actionability 
framework and provide our perspective on its use in 
development of potential treatment approaches as well as 
clinical research strategies for diverse malignancies. 
Table 1: Basis of Actionability
Biomarker Criteria Definition of Biomarker Criteria Example*
Functional in driving the malignancy and 
can be targeted by approved drug(s)
Biomarker is a direct target of one or more approved drugs, 
and targeting it will interfere with malignant cell growth. ALK
Functional in driving the malignancy and 
can be targeted by investigational drug(s)
Biomarker is a direct target of one or more investigational 
drugs, and targeting it will interfere with malignant cell 
growth. 
AKT1
Direct component of an actionable 
pathway that can be targeted by approved 
and/or investigational drugs
Biomarker may not be directly targeted by approved or 
investigational drugs, but instead is part of a pathway that 
drives the malignancy and can be directly targeted by drugs. 
PTEN
Indirect component of an actionable 
pathway that can be targeted by approved 
and/or investigational drugs
Biomarker itself may not be directly targeted by approved 
or investigational drugs, but influences the activity or 
expression of other proteins that can be targeted by either 
approved and/or investigational drugs. 
FBXW7
Homologous to an actionable 
biomarker that can be either directly or 
indirectly targeted by approved and/or 
investigational drugs
Biomarker itself may not be a target for clinically available 
drugs, but may be homologous to biomarkers that are 
targetable.
GNAO1
Can be targeted by drug(s) even if the 
biomarker is not itself functional in 
driving the malignancy
Biomarker may not be functionally important in the 
malignancy, yet can be expressed aberrantly or differentially 
in cancer cells and, hence, exploited for targeted delivery.
CD20, 
CD30
* See text for more information
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Basis of Actionability
A conceptual framework for basis of actionability 
is outlined in Table 1. Briefly, the framework divides 
biomarkers into those that do or do not have a function 
directly important to tumor pathogenesis. It should 
be kept in mind, however, that these dichotomies are 
sometimes blurred. For instance, passenger mutations 
can at times be indirectly related to or responsible for 
development of functional changes and, regardless, 
can generate therapeutic vulnerabilities in cancer [11]. 
Further stratification includes those biomarkers that can 
be targeted directly versus indirectly by approved versus 
investigational drugs, and finally those that may be 
homologous to each of the types of biomarkers mentioned 
above. 
Biomarker that is functional in driving the malignancy 
and can be targeted by approved drug(s):
A biomarker may be considered actionable if it 
is a direct target of one or more approved drugs, and if 
targeting it will interfere with malignant cell growth. The 
ALK-inhibitor crizotinib is approved for the treatment of 
ALK-rearranged non-small cell lung cancer [12-14]. It 
also inhibits MET [15] and ROS1 [16] kinases and may 
be a potential therapeutic option for cancers with driver 
aberrations in these genes. 
Biomarker that is functional in driving the malignancy 
and can be targeted by investigational drug(s): 
A biomarker may be considered actionable if it is 
a direct target of one or more investigational drugs, and 
targeting it will interfere with malignant cell growth. For 
example, several investigational drugs, such as MK-2206 
and GDC-0068, inhibit AKT1 [17-19] and clinical trials 
with these agents may be treatment options to consider for 
cancers with activating AKT1 aberrations.
Biomarker is a direct component of an actionable 
pathway that can be targeted by approved and/or 
investigational drugs:
 A biomarker may not be directly targeted by 
approved or investigational drugs, but instead it may be 
part of a pathway that drives the malignancy and can 
be directly targeted by drugs. For example, the tumor 
suppressor PTEN is not currently the target of a drug or 
class of drugs. However, reduced PTEN function leads to 
increased activity of the PI3K/AKT/mToR pathway [20-
22] that is targeted by drugs from several drug classes 
[19,23,24].
Biomarker is an indirect component of an actionable 
pathway that can be targeted by approved and/or 
investigational drugs: 
A biomarker itself may not be a target for clinically 
available drugs, but influences the activity or expression 
of other proteins that can be targeted by either approved 
and/or investigational drugs. For example, FBXW7 is 
not a target of clinically available drugs nor is it part of 
a pathway, but it does regulate the expression of many 
different proteins because it functions as an ubiquitin 
ligase that targets proteins for degradation. FBXW7 
directly regulates proteins such as mTOR and NOTCH1, 
both of which are targets of clinically available drugs. 
Studies have shown that cells deficient for FBWX7 
demonstrate increased levels of active mTOR [25] and 
NOTCH1 [26,27]. Thus, mTOR or NOTCH1 inhibitors 
could be effective in ameliorating the consequences of 
FBXW7 inactivation in cancer cells. 
Biomarker is homologous to an actionable biomarker 
that can be either directly or indirectly targeted by 
approved or investigational drugs:
A biomarker itself may not be a target for clinically 
available drugs, but may be homologous to biomarkers 
that are targetable. For example, GNAO1 is a member 
of the G-alpha protein family of GTPases and shares 
homology with GNAQ and GNA11, biomarkers that 
predict responsiveness to MEK inhibitors [28,29]. 
Knowledge about GNAQ or GNA11 may help inform 
potential treatment approaches for GNAO1-aberrant 
cancers. The other aspect of this homology is the finding 
of new mutations. For instance, if a new, previously 
un-described mutation is found in BRAF, can that be 
considered actionable in a manner similar to known BRAF 
mutations? One solution may be to model the homologous 
biomarker or the new mutation in silico and/or perform 
pre-clinical experiments and determine if it is predicted 
to be activating in a manner similar to BRAF V600E (in 
the case of a novel BRAF mutation) or the homologous 
biomarker.
The presence of the biomarker/aberration can be 
targeted by drug(s) even if the biomarker is not itself 
functional in driving the malignancy: 
A biomarker may not be functionally important 
in the malignancy, yet can be expressed aberrantly or 
differentially in cancer cells and, hence, can be exploited 
for targeted delivery. One example, is the CD20 antigen, a 
B-cell–specific differentiation antigen expressed on mature 
B-cells and in most B-cell non-Hodgkin’s lymphomas 
[30]. Several antibodies targeting CD20 exert their anti-
tumor effect by complement-dependent cytotoxicity, 
antibody-dependent cell-mediated cytotoxicity, and/
or through antibody binding to antigen leading to anti-
proliferative or apoptotic effects on cells expressing the 
target antigen [30]. Rituximab is a CD20-directed cytolytic 
antibody approved for CD20-positive Non-Hodgkin’s 
lymphoma or chronic lymphocytic leukemia [31,32]. 
Another example is the CD30 antigen, which is expressed 
by normal activated lymphocytes and is highly expressed 
by some malignant cells [33]. Brentuximab vedotin is 
an antibody-drug conjugate that consists of an antibody 
targeting the CD30 antigen linked to a chemotherapeutic 
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agent monomethyl auristatin E (MMAE), which inhibits 
microtubule polymerization [34]. Brentuximab vedotin 
is approved for Hodgkin’s lymphoma and systemic 
anaplastic large cell lymphoma, both of which express 
high levels of CD30 [14].
Rationale for Actionability
The possible rationales for actionability are 
summarized in Table 2. Briefly, rationales range from a 
drug approved with a companion diagnostic, through 
NCCN guidelines for a biomarker, to clinical trials with 
a biomarker, pre-clinical evidence for a biomarker, and 
evidence in hereditary (genetic) disease regarding a 
biomarker with possible extrapolation to malignancy. 
Biomarkers approved as companion diagnostics or those 
in FDA and NCCN guidelines have the highest level of 
support for their actionability. 
Drug approved with companion diagnostic: 
Several drugs are now approved for cancers with 
specific aberrations thus making the corresponding 
biomarkers actionable. For example, vemurafenib [14] 
and dabrafenib [35] are approved for the treatment of 
melanoma with BRAF V600E aberrations; trametinib 
is approved for melanoma with BRAF V600E or BRAF 
V600K aberrations [36]. Trastuzumab, pertuzumab, 
lapatinib, and trastuzumab emtansine are approved for the 
treatment of breast cancer with HER2 overexpression [37], 
and imatinib is approved for the treatment of KIT-positive 
gastrointestinal stromal tumors (GISTs) [38]. 
Therapeutic approach outlined in treatment guidelines 
(such as FDA or NCCN guidelines):
A biomarker may be considered actionable if 
standard clinical treatment guidelines recommend that 
cancers with aberrations in that biomarker should (or 
should not) be treated with certain drugs and drug classes. 
For example, standard treatment guidelines recommend 
KRAS and NRAS testing for colorectal cancer patients and 
that patients with KRAS- and NRAS-mutated colorectal 
cancer not be treated with epidermal growth factor 
receptor inhibitors such as cetuximab and panitumumab 
[39-44] .
Another example is EGFR, where standard treatment 
guidelines recommend testing for EGFR mutations in 
patients with non-small cell lung cancer. Patients whose 
tumors harbor sensitizing EGFR mutations should receive 
the EGFR tyrosine kinase inhibitors erlotinib, gefitinib, or 
afatinib as first-line therapy [45-50].
Clinical evidence indicating responsiveness to drug 
class(es): 
A biomarker may be considered actionable if 
available clinical data suggests that the biomarker is 
predictive of therapeutic response. Clinical data may come 
from different sources, with phase 3 studies providing 
the most robust evidence, and phase 1 or 2 studies or 
retrospective studies or registry data providing less 
definitive evidence. Importantly, genomics has unveiled 
substantial complexity and heterogeneity associated 
with cancers. As such, more “rare” tumor subtypes are 
being recognized and it is increasingly evident that the 
ability to perform randomized trials to ascertain efficacy 
for these patients is a monumental hurdle. This has 
Table 2: Rational for Actionability
Biomarker Criteria Definition of Biomarker Criteria Example*
Drug approved with companion 
diagnostic
A drug is approved for cancers with an aberration in that 
biomarker. BRAF, HER2, KIT
Therapeutic approach outlined in 
treatment guidelines (e.g. NCCN 
guidelines)
Standard clinical treatment guidelines recommend that 
cancers with aberrations in that biomarker should (or should 
not) be treated with certain drugs and drug classes. 
KRAS, 
NRAS,EGFR
Clinical evidence indicating 
responsiveness to drug class(es)
Available clinical data suggests that aberrations within the 
biomarker may be predictive of therapeutic response.  
BRAF, PIK3CA, 
HER2, TP53
Clinical trials with biomarker 
aberration as an inclusion criteria 
Clinical trials seek to enroll patients whose cancers harbor 
specific aberrations in that biomarker. CDK6
Pre-clinical evidence indicating 
responsiveness to drug class(es)
Available pre-clinical data suggests that aberrations within 
the biomarker may be predictive of therapeutic response.  MAP3K9
Evidence in genetic disease with 
biomarker aberration 
Available clinical data on the therapeutic response of the 
biomarker within the context of a non-cancer disease.  TSC1
No evidence A biomarker is not considered to be actionable if there is no data on the above mentioned criteria for that biomarker. ADAMTS20
* See text for more information
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been acknowledged by regulatory agencies as well. For 
instance, the FDA approved the multikinase inhibitor 
imatinib in ultra-rare disorders such aggressive systemic 
mastocytosis, dermatofibrosarcoma protuberans, PDGFR-
rearranged myeloprofierative disease and others based on 
high response rates in small numbers of patients bearing 
the cognate biomarker that participated in phase 2 studies 
or were described in case reports [51]. Balancing the 
need for validated efficacy data versus the reality that 
cancers may be increasingly stratified by their biomarkers 
into rare subsets is therefore a defining issue for cancer 
therapeutics. Examples of the type of clinical evidence 
that might be collected follows:
a. Phase 3 studies. For instance, in a phase 3 
clinical trial, melanoma patients with BRAF V600E-
mutated melanoma had higher clinical response rates to 
treatment with the BRAF inhibitor, vemurafenib, than the 
chemotherapy, dacarbazine [6].
b. Phase 1 or 2 studies. For example, in phase 1 
clinical trials, patients with PIK3CA-aberrant cancer had 
a higher clinical response rate to treatment with PI3K/
AKT/mTOR inhibitors than patients who lacked these 
aberrations [52,53].
c. Case reports. For example, a non-small cell 
lung cancer patient whose tumor harbored a HER2 exon 
20 mutation showed tumor shrinkage on a treatment 
regimen that included anti-HER2 drugs [54,55]. Another 
example is a patient diagnosed with spindle cell neoplasm 
harboring a KIAA1549-BRAF fusion protein and PTEN 
deletion that responded to a RAF and mTOR kinase 
targeted combination inhibitor therapy [56].
d. Retrospective studies. For example, a 
retrospective study reported that patients with advanced 
cancers harboring TP53 aberrations experienced 
longer progression-free survival on treatment regimens 
containing bevacizumab [57]. 
e. Registry data. For example, genomic data 
has been compiled through The Cancer Genome Atlas 
(TCGA). This database provides a comprehensive 
overview of the genomic aberrations in a wide variety of 
cancers [58]. Similarly, registry of clinical observations 
could be collated. For instance, a breast cancer registry 
pilot program funded by Susan G. Komen for the Cure was 
compiled from September 2009 to December 2010, based 
on twenty diverse oncology practices. A major goal was 
to generate an anonymized breast cancer registry database 
to inform future quality of care and research initiatives. 
The American Society of Clinical Oncology (ASCO) has 
also envisioned creating observational registries to inform 
patient care, including data on panomics and precision 
medicine-based therapies and outcomes [59-61].
f. Navigation or umbrella studies (which may be 
histology-agnostic), that demonstrate that patients with a 
specific biomarker may respond to certain treatments [62].
Clinical trials with biomarker aberration as an 
inclusion criteria: 
An increasing number of clinical trials seek to 
enroll patients whose cancers harbor specific aberrations. 
For example, the trial NCT01164995 (Study With Wee-1 
inhibitor MK-1775 and Carboplatin to Treat p53 Mutated 
Refractory and Resistant Ovarian Cancer) is seeking 
ovarian cancer patients whose tumors harbor mutations 
in TP53. The rationale for this study is that pre-clinical 
data suggests that abrogation of the G2 checkpoint by 
inhibition of Wee-1 kinase results in sensitization of 
p53-deficient tumor cells to DNA-damaging agents [63]. 
TP53 may be considered actionable because patients 
with TP53-aberrant ovarian cancer could enroll in such 
clinical trials. Other trials seeking to match aberrations 
in specific biomarkers with therapies that either directly 
target the biomarker or indirectly with drugs that target 
downstream effects of the aberrant biomarker include the 
National Cancer Institute’s NCI-MPACT (NCT01827384) 
and LUNG-MAP (NCT02154490) trials. NCI-MPACT 
seeks to enroll solid tumor patients with mutations or 
amplifications in specific pathways, with PARP inhibitor 
ABT-888 or MK-1175 plus carboplatin given to patients 
with tumors harboring defects in the DNA repair pathway, 
the mTOR inhibitor everolimus given to patients with 
tumors having alterations in the PI3K pathway, and MEK 
inhibitor trametinib given to patients with tumors that have 
alterations in the RAS/RAF/MEK pathway. The LUNG-
MAP trial is specifically for squamous cell lung cancer 
patients that is testing 4 different targeted therapies and 
an anti-PD-L1 therapy for patients whose tumors harbor 
alterations in a number of different biomarkers including 
PIK3CA, CDK4, CDK6, CCND1, CCND2, CCND3, 
FGFR1, FGFR2, FGFR3, and HGF/c-MET.
Pre-clinical evidence indicating responsiveness to drug 
class(es): 
A biomarker may be considered actionable based 
on pre-clinical data indicating that an aberration or class 
of aberrations (e.g activating or inactivating) in the 
biomarker responds to a specific drug or drug class. For 
example, viability of lung cancer cells with an activating 
MAP3K9 aberration was inhibited by treatment with a 
MEK inhibitor [64].
Evidence in genetic disease with biomarker aberration: 
A biomarker may also be considered actionable if 
there is clinical data on the therapeutic response of the 
biomarker within the context of a non-cancer disease. For 
example, inactivating mutations in the gene TSC1 result 
in upregulation of mTOR and cause the disease Tuberous 
Sclerosis Complex [65]. The drug everolimus, an mTOR 
inhibitor, is approved for the treatment of tuberous 
sclerosis [66]. Inactivating mutations in TSC1 are also 
common in cancer [67] and based on the clinical evidence 
in a related genetic disease, mTOR inhibitors might also 
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be considered as a treatment option. 
Use of Actionability Framework in Clinical 
Decision-Making
Interpretation and use of molecular data in clinical 
decision-making often involves extrapolating predictive 
data from the tumor site of origin with the highest strength 
of evidence to a different histology under consideration by 
the physician. This may be complicated by several issues 
described below. 
Conflicting data in several cancers: 
BRAF V600E mutation are predictive of response 
to BRAF inhibitors in melanoma and have been reported 
to predict response in other BRAF-positive malignancies 
such as hairy cell leukemia [68], histiocytosis, [69] and 
thyroid cancer [70,71], but not in colorectal cancer [72]. 
Is the lack of response in colorectal cancer due to the 
presence of additional anomalies that co-occur with BRAF 
mutations, or because BRAF inhibition causes feedback 
activation of EGFR [72], or because BRAF mutations are 
not driver abnormalities in colorectal cancer? Given these 
data, should patients with another cancer harboring BRAF 
mutations be treated with BRAF inhibitors? What are the 
considerations that might inform this decision? 
One consideration is increasing evidence that 
molecular aberrations often do not segregate by histology; 
for instance, BRAF mutations can be found in a subset 
of patients with almost any cancer [73]. Indeed, it may 
be near impossible to perform definitive clinical trials of 
BRAF inhibitors in each histology that harbors BRAF 
mutations. Historically, when approving or accepting a 
drug for therapeutic application in a specific tumor type 
as defined by histology, the drug is not expected to be 
effective for all patients with that tumor type; indeed 80% 
or more of patients may not respond/benefit. Therefore, 
if we define “tumor type” by the presence of a biomarker 
(rather than by organ of origin), the same principles 
may apply. The main question that would need to be 
ascertained might be whether or not patients who have 
that tumor type (e.g. BRAF-mutated cancer) benefit from 
the therapy overall, rather than if there are salutary effects 
for each histologic subtype or patient. As with use of drugs 
when tumor type is classified histologically, an important 
consideration for therapy in tumor types classified on the 
basis of a biomarker might be comparison of potential 
efficacy to other treatment options available to the patient. 
Aberrations of unknown significance: 
What is the significance/relevance of alternative 
aberrations in a validated biomarker like BRAF whose 
impact is not known? For instance, if a new, previously 
un-described mutation is found in BRAF, can that be 
considered actionable in a manner similar to BRAF V600E 
mutations. One solution may be to model the aberration 
in silico to determine if it is predicted to be activating 
in a manner similar to BRAF V600E or characterize the 
functional effects of the aberration using in-vitro or in-
vivo experiments. However, validation of such approaches 
are needed.
Tumors are a complex collection of genetic alterations: 
A recent study examined the distributions of 
mutation frequencies, types and contexts across many 
different cancer histologies using a panel of 127 
significantly mutated genes from well known (e.g. receptor 
tyrosine kinase signaling pathways) or emerging (e.g. 
histone modification) cellular processes in cancer. The 
study reported that most tumors have anywhere from 2 
to 6 aberrations in the studied genes [73]. The complexity 
is further amplified when testing for non-mutation based 
aberrations in a patient’s tumor. For example, in a recent 
single patient case study of metastatic malignant phyllodes 
tumor, a comprehensive molecular analysis was performed 
by using multiple Clinical Laboratory Improvement 
Amendments (CLIA)-certified labs on the same tumor 
sample including next-generation sequencing, whole-
genome array-based comparative genomic hybridization, 
proteomics, and immunohistochemistry, which revealed 
mutations (missense and nonsense), gene amplifications, 
gene deletions, and aberrant expression patterns in 13 
different genes [74]. Given this, how does an oncologist 
formulate a treatment approach or a clinical researcher 
design a research strategy that comprehensively addresses 
all the aberrations detected in a patient’s tumor specimen? 
One potential solution is a systems biology approach to 
examine the phenotypic convergence of a collection of 
aberrations in a tumor at the molecular level, i.e. are one or 
more pathways unregulated, and to determine a treatment 
approach or research strategy based on identifying 
oncogenic hubs. In many instances even in patients who 
are exceptional responders to a therapy, a genomic basis 
of drug sensitivity may not be identified and in such cases 
proteomic or transcriptomic approaches may be helpful 
in identifying pathways of resistance and / or response 
[75,76].
CONCLUSIONS
Diagnostic laboratories are now offering tests that 
interrogate tumors by sequencing either gene panels or 
full exomes/genomes in cancer samples. The degree to 
which genomic biomarkers can be successfully prosecuted 
is, however, not yet fully elucidated. For some of these 
tests, like BRAF V600E, it is clear that the aberration is 
a functionally important mutation, approved drugs are 
available to target it, and specific guidelines for the use 
of the molecular diagnostic and the cognate drug are 
available. However, for the majority of these tests, the 
extent to which the test data are usable is less clear. To 
optimize deployment of molecular diagnostic profiling, 
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more research is needed. Clinical trials or registries 
designed to examine scientifically informed theories as 
to the predictive value of certain biomarkers for carefully 
selected targeted therapies or to catalogue the genetic 
constituency of tumors and the response to various 
treatments are ways in which the clinical value of “new” 
biomarkers can be optimized, and test information about 
a biomarker can be exploited to inform patient care. We 
have provided a perspective on actionability of biomarkers 
that could be used to highlight areas of needed pre-clinical, 
clinical, or pharmaceutical research, as well as to inform 
discussions regarding consensus guidelines in this new 
frontier of biomarker discovery and utilization. 
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